Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design

BACKGROUND: The symptom severity of a substantial group of schizophrenia patients (30–40%) does not improve through pharmacotherapy with antipsychotic medication, indicating a clear need for new treatment options to improve schizophrenia outcome. Meta-analyses, genetic studies, randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasib, Lyliana G., Sommer, Iris E., Winter - van Rossum, Inge, de Vries, Jacqueline, Gangadin, Shiral S., Oomen, Priscilla P., Judge, Gurmeet, Blom, Renske E., Luykx, Jurjen J., van Beveren, Nico J. M., Veen, Natalie D., Kroken, Rune A., Johnsen, Erik L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278136/
https://www.ncbi.nlm.nih.gov/pubmed/32513294
http://dx.doi.org/10.1186/s13063-020-04365-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278136/
https://www.ncbi.nlm.nih.gov/pubmed/32513294
http://dx.doi.org/10.1186/s13063-020-04365-4

Ejemplares similares